Herpes Genitalis clinical trials
The registry lists 70 studies for Herpes Genitalis across more than 10 countries. 3 are recruiting or about to start. 52 of them are mainly about Herpes Genitalis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.
Get an email when these change. Save the Herpes Genitalis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
University of Washington (8) · GlaxoSmithKline (7) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Glaxo Wellcome (4) · Novartis (4) · Genocea Biosciences, Inc. (3) · French National Agency for Research on AIDS and Viral Hepatitis (3) · Roxane Laboratories (2)
What is being tested here
Drugs under test in Herpes Genitalis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Mar 2027A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination · Changchun BCHT Biotechnology Co.
Who these studies take
Of the 1 Herpes Genitalis studies recruiting now, 0 (0%) set no upper age limit and 1 (100%) stop at 75 or younger. 0 (0%) take children under 18. 1 (100%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 1 (100%) | 0 (0%) |
| 30 | 1 (100%) | 0 (0%) |
| 40 | 1 (100%) | 0 (0%) |
| 50 | 1 (100%) | 0 (0%) |
| 65 | 0 (0%) | 0 (0%) |
| 75 | 0 (0%) | 0 (0%) |
| 85 | 0 (0%) | 0 (0%) |
Across all 70 studies, recruiting or not: 43% stop at 75 or younger and 43% at 65; 16% take children; 11% are for women only and 4% for men only; 31% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 14, 2026.
Studies
Recruiting first, then most recently updated. Showing 50 of 70. Browse all 70 → or search them.
- A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-VaccinationEnrolling by invitationNCT07330440Phase 11 country
- Treating Genital Herpes Infection to Reduce Racial Disparities in the Risk of Severe Maternal MorbidityRecruitingNCT054293461 country
- Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital HerpesNot yet recruitingNCT04979975Phase 2
- A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital HerpesCompletedNCT05298254Phase 1/28 countries
- Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes InfectionCompletedNCT01915212Phase 11 country
- A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes LesionsActive, not recruitingNCT05432583Phase 11 country
- A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital HerpesCompletedNCT06033261Phase 1/21 country
- A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-5366 in Healthy Participants and Participants Seropositive for HSV-2 With Recurrent Genital HerpesCompletedNCT06385327Phase 12 countries
- A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital HerpesCompletedNCT06698575Phase 13 countries
- An Epidemiological Study to Assess Performance of Using Healthcare Tools to Understand Genital Herpes Simplex Virus-2 (HSV-2) in Patients ≥ 18 Years of Age in the United States and Europe.CompletedNCT049507126 countries
- NOWDx Test for the Diagnosis of Herpes Simplex Virus Type 2WithdrawnNCT042940301 country
- Study of 2LHERP® in Genital Herpes InfectionsTerminatedNCT04235322Phase 41 country
- Safety and Efficacy Comparator Trial of a New Drug Against Genital HerpesTerminatedNCT01658826Phase 21 country
- Effect of HSV-2 Suppressive Therapy on Sexual BehaviorTerminatedNCT00495716Phase 41 country
- A Study of the Characteristics of Patients Diagnosed With Recurrent Symptomatic Genital Herpetic DiseaseCompletedNCT055000531 country
- Knowledge of Young Adults About Genital HerpesStatus unknownNCT056752281 country
- Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2TerminatedNCT04222985Phase 11 country
- A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621Status unknownNCT03595995Phase 2
- UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the GenitalsStatus unknownNCT04714060Phase 2
- Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 InfectionCompletedNCT04165122Phase 21 country
- Melatonin Effects on Genital Herpes in Brazilian WomenCompletedNCT03831165Phase 41 country
- Randomized Trial to Evaluate Suppressive Effect of High-Dose Acyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2CompletedNCT00362297Phase 41 country
- Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital HerpesCompletedNCT01687595Phase 21 country
- Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital HerpesCompletedNCT01281007Phase 31 country
- Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer KagocelCompletedNCT046641271 country
- A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected PersonsTerminatedNCT00079911Phase 43 countries
- The VIBLOK SAfety and perFormancE TrialCompletedNCT03080961Not applicable1 country
- Impact Evaluation of a School-Based Sexuality and HIV Prevention Education Activity in South AfricaCompletedNCT04205721Not applicable1 country
- Safety and Efficacy of Laser Therapy in GynaecologyStatus unknownNCT040730821 country
- Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA VaccineCompletedNCT02837575Phase 21 country
- Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes InfectionTerminatedNCT03146403Phase 21 country
- A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.CompletedNCT00158860Phase 45 countries
- Herpes Simplex Virus Type 2 (HSV-2) Suppression to Prevent HIV TransmissionCompletedNCT00194519Phase 37 countries
- Trial to Study the Effect of Dose of Herpes Simplex Virus-2 (HSV-2) Suppressive Therapy on HSV and HIVCompletedNCT00527618Phase 41 country
- Evaluating New Formulation of Therapeutic HSV-2 VaccineCompletedNCT02515175Phase 21 country
- VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2CompletedNCT00306293Phase 41 country
- Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals?CompletedNCT00860977Phase 34 countries
- VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.CompletedNCT00116844Phase 41 country
- Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed ConditionsCompletedNCT01132716Not applicable1 country
- Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting ConditionsCompletedNCT01132729Not applicable1 country
- A Study With ASP2151 in Subjects With Recurrent Episodes of Genital HerpesCompletedNCT00486200Phase 21 country
- Long-term Follow-up of GEN-003-002 Subjects for Efficacy and ImmunogenicityCompletedNCT029102841 country
- Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)CompletedNCT01390805
- Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2CompletedNCT01346475Phase 41 country
- A Randomized Trial to Evaluated the Suppressive Effect of Acyclovir on Rapidly Cleared HSV-2 ReactivationCompletedNCT00723229Phase 41 country
- Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of FoodCompletedNCT02852876Phase 11 country
- A Study to Investigate the Efficacy, Safety and Tolerability of PEG in Patients With Genital HerpesTerminatedNCT01765114Phase 21 country
- GUD Clinical and Virologic Response to Acyclovir in HIV Negative African WomenCompletedNCT00808405Not applicable2 countries
- Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital HerpesCompletedNCT00171990Phase 31 country
- Safety and Efficacy of Famciclovir in HIV1 Positive Adults With Recurrent Genital HerpesCompletedNCT01154543